You are here

A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Berlin, , 14050 Germany
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Asthma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Reversible asthmatic patients (>15% increase in FEV1 following 200ug salbutamol).

- FEV1 greater than or equal to 60% predicted

- Stable disease for at least the previous 3 months

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects requiring rescue medication on greater than 2 occasions in the 72 hours prior
to screening

- Subjects with a history of pulmonary disease other than asthma.

NCT00468975
Pfizer
Completed
A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now